We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.205 | -0.75% | 27.28 | 27.245 | 27.29 | 27.75 | 27.245 | 27.545 | 161,392 | 18:31:39 |
From Apr 2019 to Apr 2024
By Cecilia Butini
Bayer AG said Wednesday that its CHRONOS-3 Phase 3 study for a combination of two drugs to treat relapsed indolent non-Hodgkin's Lymphoma has met its primary endpoint of significantly prolonging patients' progression-free survival.
Progression-free survival is understood as the amount of time after treatment that a patient can live with a disease without it worsening.
The German chemicals and pharmaceuticals major said the study examined a combination of copanlisib and rituximab, and that no new safety signals were identified in the combination. Safety and tolerability of the two drugs combined were consistent with previously available data on the drugs taken individually, the company said.
Copanlisib is already approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with relapsed follicular lymphoma, Bayer said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 14, 2020 03:19 ET (07:19 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
